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EXECUTIVE SUMMARY
In January 2002, the Commission adopted a Strategy for Europe on Life Sciences and
Biotechnology, consisting of two parts –policy orientations and a 30 point plan to transform
policy into action.
The Commission intends to report regularly on the progress made. This report is the first such
response. It sets out what has been achieved in policy development and on the ground, and
anticipates emerging issues. Where further action is needed, this report contains future
orientations, makes appropriate recommendations or announces new initiatives.
This Communication highlights a number of core issues which are fundamental to the success
of the Action Plan. It is supported by a Commission Staff Working Paper which sets out both
short and medium term actions to bring these about, as well as a more precise timetable for
delivery by the Commission.
With this Communication, the Commission is responding to the request from the Barcelona
European Council to report on progress in advance of the 2003 Spring European Council.
The Commission strategy on Life sciences and Biotechnology has been regarded as a major
initiative and as an achievement ……
The European Institutions have supported the integrated approach proposed by the
Commission as the way to work towards the Lisbon objective of promoting this high-
technology area because of its potential to create growth and new jobs and benefit a wide
range of sectors, while at the same time contributing to our broader goals, such as sustainable
development. On 26 November, the Competitiveness Council adopted conclusions, which
included a roadmap for Member States (and the Commission) identifying priority actions,
responsibility and timetable for implementation. Together with the action plan these
conclusions have established a sound framework for developing biotechnology policy
Europe-wide on a collaborative basis. On 21 November, the European Parliament gave a
strongly positive signal in support of the development of biotechnology in Europe when it
adopted, by a large majority, a resolution endorsing the Commission's biotechnology strategy.
Member States and the regions, academia and the private sectors are already identifying
measures and contributing to its implementation in many areas. This strategy presents an
integrated policy in this area at European Union level, covering both the promotion of
biotechnology development and the responsible governance of this process.
In line with the timetable set out in the Action Plan, the Commission has moved forward on a
wide range of specific actions within its own jurisdiction and has supported various
independent actions undertaken by the regions, academia and industrial organisations alike. In
some Member States a number of measures are already in place which tie in with the
Biotechnology Strategy. Although the implementation of the strategy is still at an early stage,
a certain amount of progress has been made. A notable achievement has been the adoption of
the 6
th Framework Programme for Research & Technological Development (FP6), which will
continue to underpin basic scientific research and help to build a European research system.
Considerable progress has been made on the regulatory framework for GMOs.3
……but progress in some crucial areas needs to accelerate
In some areas, including areas which might seriously risk impeding the long-term success of
biotechnology in the Union, and might also have global repercussions, the picture is more
mixed and is already giving cause for concern. These are the need for more research and
financial resources, the need to complete the system of Intellectual Property protection and
the delay in the areas of GMOs. These shortcomings have direct consequences in a number of
areas, namely in innovation, competitiveness and research in European biotechnology, and in
trade.
European biotechnology lags behind the US in terms of patents and collaborative R&D
projects and this principal competitor of ours has a dominant lead in innovative activities,
while a rapid decline in GMO field research has been reported in the EU over the last four
years. This raises the risk of failing to meet the objective of the Lisbon process in the area of
life sciences and biotechnology. Decisive action is now needed in a number of areas identified
in this report.
Like any scientific progress, the rapid advances in life sciences create high expectations for
curing diseases and improving quality of life while at the same time raising concern as to their
ethical and social consequences. Public authorities at large have to take into consideration
concerns about the conditions under which fundamental choices are made in this field. For its
part, the Commission is committed to ensuring that the ethical, legal, social and wider cultural
aspects, as well as the different underlying ways of thinking, are taken into account at the
earliest possible stage in Community –funded research. In particular, the issues of human
cloning and human embryonic stem cell research have provoked intense public and political
debate.  Ethical and social debate must continue to be a natural part of the research and
development process involving society as much as possible.
Finally, there is a need for a joint effort to broaden understanding on biotechnology at
international level. To this end, a multilateral consultative forum, in which a broad-spectrum
dialogue on biotechnology can be engaged, will be considered.
There continues to be a need for commitments and actions from all private and public
stakeholders involved in the Strategy
With the Strategy, the Commission committed itself to improving the coherence of policies
and actions in order to encourage an integrated approach towards all applications of life
sciences and biotechnology. The Commission is ready to continue to deliver on these
commitments.
But the Commission is only one of several stakeholders in the field. Many of the proposed
actions are substantially or wholly within the scope of Member States or private stakeholders.
The strategy can only be successful if it is accompanied by additional activities in the
individual Member States, by their setting and implementing, for example, national
biotechnology strategies. The Commission, for its part, is ready to continue to play its role of
facilitator and contribute to work undertaken by others with the specific task of ensuring a
coherent European framework.
A clear and consistent policy within the Member States on biotechnology is crucial.
Experience has shown that divergent and uncoordinated actions seriously risk reducing the
impact, effectiveness and coherence of the EU strategy in this field. Attention should be
drawn to the apparent inconsistency of, on the one hand, the conclusions of the Lisbon,4
Stockholm, Barcelona and Seville Summits setting the objective of becoming a leading
knowledge-based economy, promoting the full potential of biotechnology and calling for
more competitiveness in Europe’s biotech sector. On the other hand, there has not always
been the same clear signal when these statements are translated into binding rules and
commitments.5
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1. INTRODUCTION
In January 2002, the Commission adopted a Strategy for Europe on Life Sciences and
Biotechnology.
1 This was in response to the importance attached to life sciences by the
European Council. It proposes a comprehensive roadmap up to 2010 and puts the sector at the
forefront of those frontier technologies which are helping to take the European Union towards
its long-term strategic goal established by the Lisbon European Council in March 2000 of
becoming “the most competitive and dynamic, knowledge-based economy in the world,
capable of sustainable growth with more and better jobs…” within a decade.
This strategy set by the Commission consisted of two parts – policy orientations and a 30
point plan to transform policy into action. It set out what was needed from the Commission
and the other European Institutions, but also recommended actions for other public and
private stakeholders. The strategy therefore provides a framework and a reference both for
action undertaken by the many stakeholders concerned within their own responsibilities and
for co-operation between these stakeholders.
The Barcelona European Council examined the Action Plan and asked the Commission and
the Council to develop measures and a timetable to enable Community business to exploit the
potential of biotechnology while taking account of the precautionary principle and addressing
ethical and social concerns. It also asked the Commission to report on progress in advance of
the 2003 Spring European Council.
The Commission intends to report regularly on the progress made. This report is the first such
response. It states what has been achieved in policy development and on the ground, and
anticipates emerging issues. Its purpose is not to repeat the comprehensive outline for the
future course of action provided by the action plan. Many measures in line with the action
plan are already been developed or implemented across the EU. However, where there is a
specific need for fresh political impetus in some priority areas, this report contains
orientations for the future and appropriate recommendations or announces new initiatives.
This Communication highlights a number of core issues which are fundamental to the success
of the Action Plan. It is supported by a Commission Staff Working Paper which sets out both
short and medium-term actions to bring these about, as well as a more precise timetable for
delivery by the Commission. In the current early phase of implementation, this first report
focuses on action undertaken by the Commission and only provides occasional reference to
other stakeholder activities.
2. REACTIONS TO THE COMMISSION’S STRATEGY
The Strategy on Life Sciences and Biotechnology has been generally welcomed. Member
States and the Regions, academia and the private sectors are already identifying measures and
contributing to its implementation in many areas. It presents an integrated policy in this area
at European Union level, covering both the promotion of biotechnology development and
responsible governance of this process. It has proven possible to arbitrate between competing
interests and between different sectors to establish a common, albeit evolving approach.
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The strategy has been taken as a sign that the Community has begun to regain leadership in
this sensitive area; an area which affects an increasing number of Community policies. The
strategy, and the way in which it has been developed, provides a good example of European
governance in practice.
A short overview of the political response of the European Institutions is provided below.
Council and the European Council
In March 2002, the Barcelona European Council stressed the importance of frontier technologies as
a key factor for future growth. It welcomed the Commission’s strategic vision on Life Sciences and
Biotechnology as a basis for the future framework. It asked Council and the Commission to develop
detailed measures to implement the approach and to report on progress in good time before the 2003
European Council.
In Seville, the European Council added a request to the Council to implement the biotechnology
strategy proposed by the Commission.
The Council responded in November 2002, with the adoption of conclusions within the
Competitiveness Council, which welcomed the Commission’s Strategy and included a roadmap for
Member States (and the Commission) identifying priority actions, responsibility and timetable for
implementation.
These conclusions have established a sound framework for developing biotechnology policy
Europe-wide on a collaborative basis.
However, some Member States have not yet been able to transform the aims of those
conclusions into action in areas which are vital to the development of biotechnology and life
sciences, notably because of delays in transposing legislation concerning biotechnology
patents and in progressing with the authorisation of new Genetically Modified Organisms
(GMOs). There has also been only slow progress on the Community Patent proposal.
European Parliament, European Economic and Social Committee and Committee of the
Regions
The European Economic and Social Committee adopted its report on 24 September, welcoming the
Commission strategy and considering the Action Plan to be well-constructed, precise, dynamic and
pro-active.
On 21 November, the European Parliament gave a strong positive signal in support of the
development of biotechnology in Europe when it adopted by a large majority a resolution endorsing
the Commission's biotechnology strategy. Parliament took the opportunity to debate all aspects of
biotechnology in a single text and thus supported a clear and coherent concept of the importance of
life sciences. Parliament highlighted in particular the need for a Community Patent and for a progress
in the authorisation of new GMOs in order to stimulate innovation in this sector.
The Committee of the Regions did not take a position on the Commission's biotechnology strategy.
These responses show that the European Institutions support the integrated approach as the
way to move towards the Lisbon objective of promoting this high-technology area, realising
its potential to create growth and new jobs and benefit a wide range of sectors, while at the
same time contributing to our broader goals, such as sustainable development.8
3. OVERVIEW OF POLICY DEVELOPMENTS AND PRIORITIES FOR URGENT ACTIONS
In line with the timetable set out in the Action Plan, the Commission has moved forward on a
wide range of specific actions within its own jurisdiction and has supported various
independent actions undertaken by the regions, academia and industry organisations (See
supporting Commission Staff Working Paper for a detailed state of implementation of those
actions, including a more specific timetable for their delivery
2).
In some Member States a number of measures are already in place which tie in with the
Biotechnology Strategy.
Although implementation of the strategy is still at an early stage, a certain amount of progress
has been made.
However, in some areas, including areas which seriously risk impeding the long-term success
of biotechnology in the Union, and may also have global repercussions, the picture is more
mixed and is already giving cause for concern. These are the need for more research and
financial resources, the need to complete the system of Intellectual Property protection and to
further progress in the areas of GMOs.
These shortcomings have direct consequences in a number of areas, namely in innovation,
competitiveness and research in European biotechnology, and in relations with our
international trading partners, including developing countries.
This raises the risk of failing to meet the objective of the Lisbon process in the area of life
sciences and biotechnology.
In the recent letter of Federal Chancellor Gerhard Schröeder, President Jacques Chirac and
Prime Minister Tony Blair in anticipation to the 2003 Spring Council, the potential of
biotechnology in improving European industrial competitiveness and ensure employment
opportunities was recognised, while stressing the need to develop all aspects of European
business as a key role in the success of the Lisbon Strategy.
a) European Research
Research is the engine that drives the development of biotechnology. Greater, better and more
coherent research investments through the establishment of a true European Research Area
are a prerequisite if Europe wants to succeed in the life sciences.
The European research in general, but also in life sciences and biotechnology still suffers
from insufficient resources and from fragmentation. National and regional research
programmes are insufficiently geared up to each other and cross-border co-operation between
universities and industry is not yet widespread.
The establishments of a European Research Area will be helped by the Union’s Sixth
Framework Programme for Research & Technological Development (FP6)
3. The latters’
adoption by the Council and the European Parliament in June 2002, six months before its
entry into force, is the most visible and prominent achievement in the year since the launch of
the strategy. . It marks a decisive step towards involving Europe’s research and scientific
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networks in the fulfilment of the Lisbon agenda of economic, social and environmental
renewal.
The Sixth Framework Programme for Research & Technological Development (FP6)
The FP6 is the Union’s principal instrument for its researchpolicy. With an overall budget of €17.5
billion covering the four-year period 2003-2006, it represents approximately 5% of total public
research spending in Europe. The funding modalities have been revamped so as to enable the
mobilisation of a critical mass of expertise and resources around ambitious scientific objectives and to
have a better structuring impact on the research landscape in Europe. Universities, companies and
research centres will work together in integrated projects and will establish networks of excellence on
topics that present a European dimension. Biotechnology research is catered for in most of the FP6’s 7
thematic priorities, including biotechnology for health; nanotechnologies; food quality and safety and
sustainable development. Specific attention will be given to the participation of small and medium-
sized companies. Additional support will be provided for international scientific co-operation,
research infrastructures and mobility and training of researchers.
At the heart of FP6 is the creationof a true European Research Area, an internal market where
researchers, knowledge and technologies freely circulate. It aims to promote scientific
excellence, improve competitiveness and innovation through greater co-operation among
researchers and increase co-ordinationamog those that invest in research, including national
research programmes.
FP6 will help to address some of the outstanding problems hampering the development of
biotechnology in Europe, such as insufficient mobility, ‘brain-drain’ or our researchers,
fragmentation of research efforts and lagging transformation of research results into products
and services. This European public research effort will complement and spur the investments
made by entrepreneurial biotechnology companies, totalling€7.5 billion in researchin 2001.
Investment in research
Investment in knowledge creation is a precondition for Europe to achieve the goal set by the
European Council at Lisbon of becoming “the most competitive knowledge-based economy in
the world”. However, current level of investment in R&D is insufficient to achieve this goal.
The European Union invests 1.9 % of GDP in R&D compared with 2.7% invested by US and
3% by Japan. In 2000, the gap between US and EU investment in R&D reached €124 billion.
It has doubled at constant prices since 1994. More than 80% of this R&D gap is due to lower
funding by the EU business sector.
At the March 2002 Barcelona European Council, the EU agreed that overall spending on
R&D in the Union should be increased with the aim of approaching by 2010 3% of GDP, of
which two-third should come from the private sector. On 11 September 2002, the
Commission Communication “More Research for Europe - Towards 3% of GDP” was
adopted. With this Communication the Commission has engaged a debate with all
stakeholders on the ways and means of achieving the ambitious goal set in Barcelona. It
intends to come forward in spring 2003 with an action plan.
The Commission calls for coherent mobilisation of a wide range of policies in order to
establish framework conditions that are more conducive to private investment in R&D, and to
ensure a more effective use of public R&D financing mechanisms.10
Priorities for future actions
The life sciences and biotech industry has and will continue to have its roots in public
research. Actions agreed at European level must be matched by a solid nationally funded
research effort that delivers results at national and local levels, and that allows for
unhampered cross-border co-operation between the best researchers from public and
private sectors in dedicated fields.
b) Science and Society
Like any scientific progress, the rapid advances in life sciences have created high expectations
for curing diseases and improving quality of life but have at the same time raised concerns as
to their ethical and social consequences. Public authorities at large have to take on board
concerns about the conditions under which fundamental choices are made in this field.
For its part, the Commission is committed to ensuring that the ethical, legal, social and wider
cultural aspects, as well as the different underlying ways of thinking, are taken into account at
the earliest possible stage in Community–funded research.
Fostering informed public dialogue
As in the past, the Commission will, in the implementation of FP6 and in other action, ensure
that ethical and social debate continues to be a natural part of the research and development
process, involving society as much as possible.
In order to encourage scientists managing their projects in such an inclusive way and dialogue
with the public, the Commission calls for initiatives that integrate discussion platforms as a
strategic element of the work. Large research clusters like one on the safety assessment of
GMOs or another on probiotics have designed new ways of conducting research, with NGOs
participating as partners in the projects.
Through the FP6, the Commission supports measures to help researchers become
communicators and debaters, caring for the conditions in which all parties in society can be
involved and embarking in new ways of collective learning. One concrete example is the
“Science-Generation” project, which creates partnerships between local communities, the
media and scientists in France, Italy and Sweden.
In addition and for the first time, the FP6 now includes a Science and Society programme
which supports comparative, foresight and technology impact research linked to ethical
questions emerging in new fields of science and their applications.
Recently, two issues have provoked intense public and political debate: human cloning and
human embryonic stem cell research.
Human reproductive cloning
Recent speculation on the possibility of human reproductive cloning has reignited the debate
on its acceptability from an ethical as well as a scientific point of view. A number of
initiatives on this issue have been taken, both at national and at international level. A Franco-
German initiative on a world convention banning the reproductive cloning of human beings11
has been announced and is being discussed in the United Nations. Japan has recently
indicated its wish to join other countries in drawing up a world treaty prohibiting human
reproductive cloning.
The European Parliament has adopted a number of resolutions on the cloning of human
embryos and the ethical and legal problems of genetic engineering.
4 An EP own-initiative
report on the ethical, legal, economic and social implications of human genetics was rejected
in plenary.
5
Human reproductive cloning is prohibited by Article 3 of the Charter of Fundamental Rights
of the European Union
6. The European Group on Ethics in Sciences and New Technologies
(EGE) has also spoken out against such procedure.
7 Accordingly, the European Community’s
Sixth Framework Programme has excluded from funding any research that involves human
reproductive cloning.
The Commission reaffirms its full support for a worldwide ban on human reproductive
cloning.
Human embryonic stem cell research
The issue of human embryonic stem cell research was highlighted in the process of adopting
FP6 and its implementing measures.
8 In particular, the final discussions in the Council and
Parliament on the specific programme “Integrating and Strengthening the European Research
Area (ERA)” implementing FP6 focused on this specific issue.
Council position on research on stem cells
In the Council meeting of 30
th September 2002, the Council and the Commission agreed that detailed
implementing provisions concerning research activities involving the use of human embryos and
human embryonic stem cells which may be funded under the FP6 have to be established by 31
December 2003.Furthermore, in that occasion, the Commission stated that, during that period and
pending the establishment of detailed implementation provisions, it will not propose to fund such,
with the exception of banked or isolated human embryonic stem cells in culture.
The Commission is constantly monitoring scientific advances and needs as well as the
evolution of international and national legislation, regulations and ethical rules regarding
these issues. In so doing, it takes into account the opinions of the European Group of Advisers
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on the Ethical Implications of Biotechnology (1991-1997) and the opinions of the European
Group on Ethics in Science and New Technologies (as from 1998).
9
Priorities for future actions
In accordance with the Council declaration on the specific programme “Integrating and
strengthening the European Research Area”, the Commission will
 in Spring 2003, present a report on human embryonic stem cell research to the
European Parliament and to the Council which will form the basis for discussion at an inter-
institutional seminar on bioethics, and is expected to contribute to a Europe-wide discussion
on the ethical issues of modern biotechnology, particularly on human embryonic stem cells;
 submit a proposal, based on Article 166(4) of the Treaty, establishing further
guidelines on the principles for deciding on possible Community funding of research projects
involving in particular the use of human embryonic stem cells.
c) Competitiveness, innovation and intellectual property
There have been encouraging signs of dynamism: a wave of entry of new dedicated
biotechnology firms entering the market in a number of European countries. The European
biotech industry is a late starter and still at an early stage in terms of size of companies,
revenues and product pipeline. There is now an urgent need for further industry development
and consolidation. Biotechnology is a global, highly capital-intensive and knowledge-based
industry. Its development will thus depend on progress in overcoming the three fundamental
issues of fragmentation, access to finance and intellectual property protection.
Fragmentation and access to finance
The fragmentation that characterises research is also reflected in European industry. This is
partly due to general regulatory, entrepreneurial, fiscal and financial factors, but more
specifically also to the traditionally national nature of research spilling over to the companies
created out of that research. There is little co-operation across Member States and it has been
shown that European companies are more likely to enter into research collaboration with US
companies than with Europeans counterparts. In addition, the interface between the public
research system and industry is insufficiently developed.
Innovation and competitiveness in European Biotechnology
A study
10 shows that European biotechnology lags behind the US in terms of patents and collaborative
R&D projects and that this principal competitor of ours has a dominant lead in innovative activities.
Underpinning public basic scientific research and the ongoing establishment of a European
Research Area offers the most effective means of counteracting this fragmentation.
It is a fact that none of the biotechnology clusters in Europe at present are as dynamic in
developing companies and products as the leading US biotechnology clusters in New England
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and California. A forthcoming innovation scoreboard study of biotechnology shows that the
top performers of the EU are competitive with the US but that many have not reached a
critical mass. In the time since the Commission issued the Communication on Biotechnology
strategy there have been an increasing number of initiatives and meetings involving regions,
clusters, companies and research institutions. Europe’s regions are developing a network
based on an open membership structure and co-operation between interested parties on
specific issues. There have also been a number of other promising initiatives from the private
and academic sectors and NGOs to promote dialogue between stakeholders and the general
public. The Commission welcomes this type of activity and above all its bottom-up approach,
which should ensure that activities correspond to the priorities of the participants. Following a
recently concluded evaluation of proposals, a European biotechnology web hub will be
established in 2003 with Commission support, the aim being to provide a central linkup
function between the stakeholders in the biotechnology community.
G10 Medicines and review of the pharmaceutical legislation
In May 2002 the High Level Group on Innovation and Provision of Medicines (G10
Medicines) delivered its report
11 on ways to improve the competitiveness of the European-
based pharmaceutical industry within the context of achieving social and public health
objectives. Given the important role of biotechnology in developing tomorrow's
pharmaceutical products, the Report underlined the importance of the Commission’s
biotechnology strategy and referred, in particular, to the need to complete the implementation
of the Directive on biotechnological inventions. The Commission will respond to the report’s
recommendations in the form of a Communication that is likely to be adopted in the summer
of 2003.
Many important steps to improve the innovative capacity of European pharmaceutical
industry are taken on board in the ongoing revision of the Community’s pharmaceutical
legislation as laid down in Regulation No 2309/93 and Directive 2001/83/EC. Key elements
in the Commission’s efforts to overcome the current fragmentation of the markets and to
establish the necessary intellectual property protection are certain adaptations of the so-called
centralised procedure including increased scientific advice of the companies and harmonised
data protection periods.
The biotechnology industry is dependent on access in particular to risk capital.
Companies will have to manage a very long and costly research and development process
before they have a marketable product or in some cases fail. Public and private investors have
to be prepared to invest with a longer perspective in high-risk companies. During the last five
years Europe has been very successful in creating new biotechnology companies, but a large
proportion of those companies are now facing the need to renew their financing in a very
difficult financial market.
There is no doubt that a number of biotechnology companies are going to disappear in the
consolidation process, as some would not be viable even in good market conditions. Others
will find a future through mergers or as divisions of larger companies. This does not lessen
the fact that Europe runs the risk of losing not only a number of potentially viable companies
but also a generation of researchers and its resulting intellectual property. Europe risks losing
knowledge assets already acquired. It has therefore been realised that the main problem lies in
financing more mature companies. The Commission's advisory Biotechnology and Finance
Forum estimated a potential funding gap of up to $1 billion during 2003.
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Priorities for future actions
There is some indication of the scope and urgency of the financial situation in the
entrepreneurial biotechnology industry. The Member States, the Commission and financial
institutions now have to consider their response to ensure that Europe does not lose what
knowledge assets it has.
Intellectual property protection
A clear, equitable, affordable and effective patent regime applied consistently across the EU
is crucial if we are to exploit fully the medical, environmental and economic potential of
biotechnology in line with high ethical standards, while taking due account of public concerns
on the issue of patents granted for biotechnological innovations.
This objective involves
–  the Community Patent, and
–  the Directive on biotechnological inventions.
Patent protection in the EU is currently ensured by two systems, neither of which is based on
a Community legal instrument: the European Patent System and the national patent systems.
As a result, patenting in Europe is expensive and fraught with legal uncertainty. A
Community patent of a unitary nature valid in all Member States remains utterly desirable,
particularly in a field of global application like biotechnology. With this in mind, the
Commission has submitted a proposal for a Regulation on the Community Patent,
12 which,
after receiving the opinion of the European Parliament, is being discussed in the Council,
where, on 3 March 2003, a political agreement has been reached.
Directive 98/44/EC
13 on the legal protection of biotechnological inventions was adopted after
a long and constructive debate which lasted about ten years in both the Council and the
European Parliament. During those negotiations, it was fully recognised that biotechnological
inventions are a sector in full expansion and need a sound legal framework to allow European
businesses to develop and market the resulting products and processes. New techniques of
great promise for cures, industrial processes and foodstuffs are becoming established very
rapidly, and the European legislator considered it essential not to hamper their development.
This Directive, which is crucial for both scientific progress and innovation and
competitiveness, has been applicable since 30 July 2000. The European Patent Organisation, a
non-Community Body which grants patents having effect, among others, in the territory of the
Member States, amended its implementing regulation in 1999 in order to take account of the
provisions contained in Directive 98/44/EC.
As provided for by Article 16(c) of Directive 98/44/EC, the Commission adopted the Annual
Report of the Commission to the European Parliament and the Council on the development
and implications of patent law in the field of biotechnology and genetic engineering,
14 the aim
being to monitor developments and prevent any malfunctioning in this sector. In particular,
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the report highlights the key provisions of the Directive in the light of the judgement of the
Court of Justice of the European Communities of 9 October 2001.
15
In its judgement the Court dismissed the action for annulment brought by the Netherlands,
reiterating de jure the essential principles of the Directive and casting new light on a number of
specific provisions. In particular, the Court confirmed the scope of the Directive and its compatibility
with existing international agreements in the field of biotechnology.
The Court pointed out that the Directive complies with the fundamental rights relating to the respect
of human dignity and human integrity.
Finally, the Court also recalled the patentability of inventions relating to plants.
Despite the above, to date, only six Member States
16 have transposed Directive 98/44/EC into
their national legal systems while the other Member States are currently at varying stages of
progress. Reasoned opinions, the second stage of formal infringement proceedings under
Article 226 of the EC Treaty have been sent to the Member States concerned asking them to
transpose Directive 98/44/EC into national law.
Transposition of this Directive is a legal obligation under the Treaty and is essential in order
to avoid any discrepancies between the legislations of the Member States. This situation is
considerably hampering the development of biotechnology in Europe in comparison to our
competitors.
Priorities for future actions
  Following the political agreement of 3 March 2003, the Commission invites the Council to
resolve the remaining difficulties and to adopt the Community Patent Regulation before
the end of 2003. The Council is furthermore invited to take a timely decision for the
creation of the centralised court, for which the Commission is now able to present a
proposal to the Council in due course. Changes to the European Patent Convention will
also have to be agreed in order to allow the European Patent Office to grant Community
Patents.
  In the light of the judgement of the Court, the Commission strongly calls upon the
Member States concerned to fully and swiftly transpose and implement Directive
98/44/EC.
  For its part, the Commission will consider the following two questions identified in the
report:
a) the scope of patents relating to sequences or part-sequences of genes isolated from the
human body;
b) the patentability of human stem cells and cell lines obtained from them.
These two topics will be studied and analysed by a group of independent experts
(specialising in the fields of economics, law and natural sciences). This group will also help
the Commission to identify priority topics to be covered in future reports.
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d) Genetically Modified Organisms (GMOs)
Regulatory framework and public perception
The regulatory framework in place since 1990 on the deliberate release into the environment
of GMOs (Directive 90/220/EEC) and since 1997 on novel food and novel food ingredient
(Regulation (EC) No 258/97) have already provided for a high level of protection for human
and the environment.
Considerable progress has been made in further advancing in the regulatory framework for
GMOs, namely:
–  Directive 2001/18/EC
17, which provides for a more complete authorisation procedure for GMOs,
has been fully applicable since 17 October 2002. This Directive improves legislation on the
deliberate release of GMOs into the environment, providing a solid base for transparent and
responsible management of the use of GMOs. Furthermore, implementing measures
18 needed for
the applicability of that Directive at that date, including guidance notes on risk assessment and
monitoring, are also in place;
–  the reaching of political agreement in the Council on first readings in the European Parliament of
the two Commission proposals on genetically modified organisms (GMOs), establishing a
comprehensive Community system to trace and label GMOs and to regulate the placing on the
market and labelling of GM food and feed;
19,20
–  steps forward in the implementation of the Cartagena Protocol, which
guarantees all signatory countries the freedom to carry out a risk assessment prior
to accepting import of a new GMO. On 17 October 2002, political agreement was
reached in the Environmental Council on the Commission proposal for
transposing the Cartagena Protocol into EU legislation, which will govern exports
of GMOs.
 21
Furthermore, the European Network of GMO Laboratories (ENGL) was set up to contribute
more effectively to the uniform enforcement of legislation across the Community through the
harmonisation and standardisation of means and methods of sampling, detection,
identification and quantification of GMOs or derived products in a wide variety of matrices,
covering seed, grains, food, feed and environmental samples.
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The ENGL set out to act as a scientific and technical European Union network of excellence within
the context of EU GMO regulation.
The network was inaugurated in Brussels on 4
th December 2002 and currently
consists of 44 EU enforcement laboratories, plus Norway and a number of observers
such as Accession Countries. The GMO laboratory of the Commission’s Joint
Research Centre (JRC) will co-ordinate ENGL's activities. It will act as the EU
reference laboratory for GMO food and feed legislation.
The EU regulatory framework on GMOs and GM food and feed is one of the most thorough
and transparent regulatory framework on GMOs in the world. It aims to provide a high level
protection of human health and the environment, legal certainty for operators, address public
concerns, including ethical concerns, facilitate consumers’ choice,and thereby fosters further
public confidence on the use of GMOs.The Commission considers that it has met its
commitments to create the conditions for making the GMO authorisation procedure
operational and it is ready to play its role in managing the new procedure. Member States
should equally assume their responsibilities in order to ensure that progress is made on
authorisations. However, in spite of the improvements in the regulatory framework, public
and political concerns with GMOs continue. Whilst medical applications involving the use of
GMOs have continued to make progress, this is not the case for the use of GMOs
inagriculture, where so far there are no obvious perceived benefits for consumers.
Since October 1998, progress in the authorisation of new GMOs have been limited. However,
food products produced from GMOs have been placed on the market in the Community under
the Novel Foods Regulation,
22 on the basis of their ‘substantial equivalency’ to the
conventional products.
The deadline for transposition of Directive 2001/18/EC was 17
th October 2002. To date only
Denmark and Sweden have fully communicated its implementation measures for this
Directive. The Commission had already addressed Letters of Formal Notice to 13 Member
States for non-communication of transposition measures and is considering sending one to the
UK for partial communications of transposition measures.
The most recent in the series of Eurobarometer surveys on what the European public thinks
about biotechnology indicates that, although there may be a softening of attitudes towards
biotechnology in general, GM foods are still seen as having no benefits and to carrying risks.
Whilst public authorithies are responsible for providing a clear and predictable legal
framework for the approval of GMOs and derived products, it is primarily for the biotech
industry to openly explain and document the benefits of the use of GMOs.
The lack of progress on the authorisations of new GMOs is having a direct impact on
research activities on GMOs and GMO field trials in Europe.
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Impact on research activities and development in GMOs
A survey among private companies and research institutes active in the field of GMOs was conducted
in order to get an overview of basic and applied research activities on GMOs in Europe.
23 The survey
reveals that 39% of the respondents have cancelled R&D projects on Genetically Modified
Organisms (GMOs) over the last four years giving as the main reasons the unclear regulatory
framework and uncertain market situation. The tendency to cancel R&D projects is low for the public
sector (23  % of respondents have cancelled projects) and higher in the private sector (61  % of
respondents having cancelled projects).
Furthermore, the number of notifications for GMO field trials in the EU increased rapidly from
1991 to 1998, and declined sharply thereafter (76 % decrease by end 2001). In 2001, the
Commission’s Joint Research Centre (JRC) database, which keeps a register of EU field trials,
received just 61 notifications for field trials with GM plants, compared with over 250 in 1998. Such a
marked decrease in the number of GMO field trials has not taken place to this extent outside Europe
(e.g. in the US). According to the study, there is a response effect to the lack of progress in new
commercial release of GMOs as well as the widespread tendency of the European public to reject
GMOs.
This situation underlines the importance of a clear and predictable regulatory framework not
only for fostering consumer acceptance and providing legal certainty for operators in the
production and distribution chain, but also for reversing the rapid decline in GMO field
research in the EU.
Priorities for future actions
Against the above background, the Commission calls upon
  the Member States concerned to fully and swiftly transpose and implement Directive
2001/18/EC and not to withold new authorisation on GM products which fulfil current legal
requirements, and
  the European Parliament and the Council to adopt of the two Commission proposals on
the traceability and labelling of GMOs and on GM food and feed, at the earliest
in order to provide a modernised legal framework based on transparency and efficiency and
facilitating the freedom of choice of consumers as well as providing legal certainty for
operators.
e) International issues
Biotechnology has been increasingly adopted in the world. In the agriculture/food sector,
biotechnology has spread very quickly and continues to spread. In 2002, up to 58 millions
hectares were planted with GM crops. While the US still dominates the production of GM
food, several developing countries grew GM crops or started to authorise GMOs in
agriculture.
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Existing international forums and initiatives
Discussions on biotechnology and issues related to biotechnology take place today in a
multitude of international forums. A number of international organisations have direct
competence in dealing with issues relating to biotechnology – biosafety is addressed by the
Cartagena Protocol, biodiversity by the Convention on Biological Diversity (CBD),
agriculture by the Food and Agriculture Organisation (FAO), intellectual property rights and
technology transfer by the World Intellectual Property Organisation (WIPO) and World Trade
Organisation (WTO), trade by the WTO, risk analysis of foods derived from modern
biotechnology in Codex Alimentarius under the World Health Organisation (WHO)/FAO,
plant protection under the International Plant Protection Convention (IPPC), and the
development of consensus documents by the Organisation for Economic Co-operation and
Development (OECD).
Recently, new initiatives have been launched and other organisations have also taken up the
issue of biotechnology. The OECD organised two conferences on GM crops and feed in 2000
and 2001 with world-wide participation, the UNIDO intends to organise a Global Biotech
Forum later in 2003, the WHO is working on GM food safety, and the World Bank has
launched a consultative process on the proposed international assessment of the role of
agricultural science and technology in reducing hunger, improving rural livelihoods and
stimulating environmentally sustainable economic growth.
Need for improved dialogue
The increasing number of international initiatives reflect the different concerns and current
controversy surrounding biotechnology and raises a more fundamental question relating to
international governance. Each of the above organisations plays an essential role in their
specific area. However, none appears to provide an adequate forum for promoting an open
and transparent dialogue between all the stakeholders concerned. Such a dialogue, on all the
issues at stake in biotechnology, would facilitate mutual understanding of the concerns and
objectives of the different countries and regions. Without it, there is a risk that the approach to
biotechnology in the international system will become too fragmented, incoherent and
overlapping. It is also increasingly difficult for developing countries to afford the resources to
participate in all of the on-going activities.
Improved dialogue is particularly important where regulatory requirements and the concerns
of countries and regions are going in different directions. In particular, the current
developments in the EU regulatory framework are being closely followed by a number of
third countries, some of which have expressed strong reservations regarding the
implementation of existing legislation and the design of future rules.
The economic stakeholders and interests involved in the production of GM- crops extend well
beyond national frontiers. Therefore, governing biotechnology innovation means finding a
way of laying down common rules and principles on a global scale while still respecting the
pursuit of legitimate approaches in different parts of the world. This is proving to be a
difficult challenge. Resorting to legal challenges or showing disrespect for the legitimate
rights of governments is not going to solve the public concerns expressed in different
countries, and would most likely lead to more controversy and polarisation.
The current divergence of views between the EU and some of its trading partners is adding to
the perception of a lack of "international governance" in the field of biotechnology,
particularly for agricultural biotechnology.20
The most salient example is the reported threat from certain Third Countries of a WTO
challenge against the EU biotechnology legislation.
Threats of a WTO legal challenge
At the November 2002 meeting of the World Trade Organisation (WTO) Committee on Sanitary and
Phytosanitary Agreement (SPS), the US, Canada, Argentina and the Philippines again raised their
concerns regarding the EU’s continued handling of the approval of new GMOs and on the WTO
compatibility of new and forthcoming European legislation, namely the Commission proposals on the
traceability and labelling of GMOs and on GM food and feed.
The introduction of GMOs in agriculture raises several issues among which human health,
environment, the economically viable co-existence of different agricultural production
systems, intellectual property rights and trade.
Many developing countries have not yet developed a policy to address these issues and
several still lack the capacity to develop and enforce biotechnology legislation.
GM crops and developing countries
The recent food crisis in Southern Africa and the GMO- content of related food aid supplies has once
again brought to the public attention the issue of the introduction of GMOs into certain developing
countries.
The recent controversy has been sparked by the US supply of substantial amounts of food aid as a
response to the serious food shortage in Southern Africa. US-supplied maize contains grain from
varieties which are genetically modified.
Some countries in the region
24 initially refused to take the maize for several reasons, among which
human health concerns, environmental considerations, intellectual property rights concerns, the risk of
spread of transgenes into their own maize production, and the repercussions such a spread could have
on regional and international trade.
The Commission considers that all countries have the right to take the measures they deem
appropriate to control the intentional or unintentional dissemination of genetically modified
organisms in their territory. However, regulations should, as a general principle, take into
account the current degree of scientific knowledge, be transparent and predictable, and should
not be more trade-restrictive than is necessary to fulfil their objectives, taking into account the
level of protection sought. There is a need to improve international governance in the field of
biotechnology and to ensure that different regulatory mechanisms can co-exist.
To date, the EU-US Biotechnology Consultative Forum, launched by President Prodi and
President Clinton in May 2000, remains as a unique example of an independent group of
experts representing diverse views on the two sides of the Atlantic. The Forum was a useful
exercise in promoting understanding of, and consensus on some of the difficult and
contentious issues that underlie the different points of view on biotechnology within the EU
and the US and between the respective governments. Because of the background and causes
of the controversies surrounding biotechnology and its rapid evolution, the Forum made a
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number of recommendations including further work and analysis. The Commission has made
its position on the Forum’s recommendations public
25 and is willing to continue dialogue
towards a co-operative solution to the issues at stake.
The initiative of an international process designed to engage a broad range of stakeholders has
indeed been considered in the recent past. In fact, at the Okinawa Summit in July 2000, the
G8 agreed “to explore, in consultation with international organisations and interested bodies
including scientific academies, the way to best integrate the best scientific knowledge
available into the global process of consensus building on biotechnology and other aspects of
food and crop safety”. After the tragic events of 11September 2001, the G8 has been
preoccupied with combating terrorism and, thus, the issue of food safety and biotechnology
has been deferred.
On 30 and 31 January 2003, the Commission organised a conference in Brussels on the
subject of biotechnology in agriculture in developing countries. The conference attracted
more than 900 participants from all over the world, including scientists, government
representatives, NGOs, industry, media.
Priorities for future actions
It is time to give further consideration to the need for a multilateral consultative forum to
facilitate open and balanced dialogue, including all stakeholders and to promote better
consistency of the agreements achieved in the different forums.
Such a consultative body should be capable of fostering a wide spectrum of interests,
including scientists and a cross section of civil society, the aim being to contribute to the
process of international consensus building on issues relating to biotechnology without
duplicating on-going work in established international forums. Such an initiative should be
intended as an essential step towards a better global understanding of the issues relating to
the application of biotechnology and the differences in regulatory approaches amongst
regions and countries.
The Commission will pursue this matter further with a view to verifying the feasibility of such
a forum and the willingness of our trading partners to engage in such a dialogue. The
Commission will also support an independent review of existing scientific knowledge
concerning agricultural biotechnology in the context of developing countries.
4. Overall conclusions
–  The Commission strategy on Life sciences and Biotechnology has been widely regarded as
a major initiative and as an achievement.
–  With the Strategy, the Commission committed itself to improving the coherence of policies
and actions in order to encourage an integrated approach towards all applications of life
sciences and biotechnology. The Commission is ready to continue to deliver on these
commitments.
–  Progress has been made in some areas, but others are suffering from serious delays. There
is a need for commitments and actions from all private and public stakeholders involved in
the Strategy. The Commission is only one of several stakeholders in the field. Many of the
proposed actions are substantially or wholly within the jurisdiction of the Member States
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or private stakeholders. The strategy can only be successful if it is accompanied by
additional activities in the individual Member States, by setting and implementing, for
example, national biotechnology strategies. The Commission, for its part, is ready to
continue to play its role of facilitator and contribute to work undertaken by others with the
specific task of ensuring a coherent European framework. The Council conclusions of
November 2002 are a major contribution to this framework. A concerted effort is now
needed to continue the process of implementation.
–  A clear and consistent policy in the Member States on biotechnology is crucial. Experience
has shown that divergent and uncoordinated actions seriously risk reducing the impact,
effectiveness and coherence of the EU strategy in this field. Attention should be drawn to
the apparent inconsistency of, on the one hand, the conclusions of the Lisbon, Stockholm,
Barcelona and Seville Summits setting the objective of becoming a leading knowledge-
based economy, promoting the full potential of biotechnology and calling for more
competitiveness in Europe’s biotech sector. On the other hand, there has not always been
the same clear signal when these statements are translated into binding rules and
commitments. In particular, the maintenance of a situation of legal uncertainty, notably the
delay in progress in the area of GMOs, and the non-transposition of EC legislation on
patents along with the delay in setting up a unitary Community patent, is having an impact
on competitiveness, research capabilities and trade. Decisive action in now needed in a
number of areas identified in this report.
–  The regulatory framework on GMOs, including the Commission’s proposals on
traceability and labelling of GMOs and on GM food and feed provides for a high level of
protection for human health and the environment, legal certainty for operators, addresses
public concerns and facilitates consumers’ choice, and thereby fosters further public
confidence on the use of GMOs. It is also important that the regulatory framework is clear
and predictable if the rapid decline in GMO field research in the EU is to be reversed.
–  Like any scientific progress, the rapid advances in life sciences create high expectations for
curing diseases and improving quality of life while at the same time raising concerns as to
their ethical and social consequences. Public authorities at large have to take on board
concerns about the conditions under which fundamental choices are made in this field. For
its part, the European Commission is committed to ensuring that the ethical, legal, social
and wider cultural aspects, as well as the different underlying ways of thinking, are taken
into account at the earliest possible stage in Community–funded research.  Ethical and
social debate must continue to be a natural part of the research and development process,
involving society as much as possible.
–  Finally, there is a need for a joint effort to broaden understanding on biotechnology at
international level. To this end, a multilateral consultative forum, in which a broad-
spectrum dialogue on biotechnology can be engaged, will be considered.